Zydus Lifesciences Limited has signed an exclusive agreement with Myriad Genetics, a US-based leader in molecular diagnostic testing and precision medicine. This collaboration will introduce MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus (Homologous Recombination Deficiency Test), and Prolaris® Prostate Cancer Prognostic Test to patients, clinicians, and healthcare systems across India. The MyRisk® Test is designed to help individuals assess their hereditary cancer risk, enabling them to take precautionary steps. For patients diagnosed with prostate and ovarian cancers, the Prolaris® Test and MyChoice® HRD Plus Test, respectively, will provide insights into disease progression and guide appropriate treatment paths. Dr. Sharvil P. Patel, Managing Director of Zydus, stated that this agreement is a significant step in broadening access to precision diagnostic tests for cancer treatment in India. He highlighted that these tests offer actionable insights for developing personalized treatment plans, predicting disease progression, and streamlining clinical workflows. The collaboration aims to make personalized, evidence-based cancer care accessible to all patients in need. Brian Donnelly, Chief Commercial Officer for Myriad Genetics, emphasized that the collaboration with Zydus is crucial for advancing precision oncology in India. Myriad's tests are intended to equip clinicians with actionable information for risk assessment, understanding tumor biology, and guiding personalized care. Under the agreement, Zydus will exclusively market and promote Myriad Genetics' MyRisk® Hereditary Cancer Test, MyChoice® HRD Plus Test for ovarian cancer, and Prolaris® Prostate Cancer Prognostic Test in India. These diagnostic platforms have been widely adopted globally and will now provide Indian oncologists with advanced genomic decision-support tools. The MyRisk® Test analyzes 63 genes and includes RiskScore® for breast cancer risk assessment, while the MyChoice® HRD Plus Test assesses HRD status for ovarian cancer patients, and the Prolaris® Test quantifies prostate cancer aggressiveness to aid treatment decisions.
